Johnson & Johnson (NYSE:JNJ) Shares acquired by Elo Mutual Pension Insurance Co


Elo Mutual Pension Insurance Co boosted its position in Johnson & Johnson (NYSE:JNJ – Get Rating ) by 2.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 203,647 shares of the company’s stock after acquiring an additional 5,742 shares during the period. Johnson & Johnson makes up about 1.0% of Elo Mutual Pension Insurance Co’s portfolio, making the stock its 14th largest holding. Elo Mutual Pension Insurance Co’s holdings in Johnson & Johnson were worth $36,092,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sloy Dahl & Holst LLC boosted its holdings in Johnson & Johnson by 7.5% in the first quarter. Sloy Dahl & Holst LLC now owns 6,245 shares of the company’s stock valued at $1,107,000 after purchasing an additional 436 shares during the period. WMS Partners LLC boosted its holdings in shares of Johnson & Johnson by 3.5% in the first quarter. WMS Partners LLC now owns 75,996 shares of the company’s stock valued at $13,469,000 after acquiring an additional 2,586 shares during the last quarter. State Treasurer State of North Carolina raised its stake in shares of Johnson & Johnson by 1.2% during the first quarter. State Treasurer State of North Carolina now owns 1,171,014 shares of the company’s stock valued at $207,539,000 after acquiring an additional 14,123 shares during the period. Advisors Capital Management LLC boosted its holdings in shares of Johnson & Johnson by 6.1% in the first quarter. Advisors Capital Management LLC now owns 284,971 shares of the company’s stock valued at $50,505,000 after buying an additional 16,467 shares during the last quarter. Finally, SILVER OAK SECURITIES Inc acquired a new position in Johnson & Johnson during the first quarter valued at $1,200,000. Institutional investors and hedge funds own 68.78% of the company’s shares.

Johnson & Johnson Trading up 1.5%

Shares of Johnson & Johnson stock opened at $169.31 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The firm has a market cap of $445.15 billion, a PE ratio of 24.64, a P/E/G ratio of 3.17 and a beta of 0.59. The firm’s 50-day moving average is $173.43 and its 200-day moving average is $174.56.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The business had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. In the same quarter last year, the business posted $2.48 earnings per share. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. On average, sell-side analysts forecast that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be paid a $1.13 dividend. This represents an annualized dividend of $4.52 and a dividend yield of 2.67%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is 65.79%.

Insider dealings at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The sale was disclosed in a filing with the SEC, which can be accessed via this hyperlink. In other news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00 for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The transaction was disclosed in a filing with the Securities and Exchange Commission, which is available on the SEC’s website. Also, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at approximately $2,785,140. Disclosure of this sale can be found here. Insiders own 0.35% of the company’s stock.

Analysts set new price targets

A number of research firms have weighed in on JNJ. Morgan Stanley lifted their price objective on Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a research note on Friday, July 8th. UBS Group reduced their price objective on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Daiwa Capital Markets began coverage on shares of Johnson & Johnson in a research note on Wednesday, June 22nd. They assign an “outperform” rating to the stock. SVB Leerink cut their target price on shares of Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Finally, Citigroup decreased their price objective on shares of Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Moderate Buy” and a consensus target price of $189.89, according to MarketBeat.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and markets a variety of health care products worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under AVEENO, CLEAN & CLEAR, DR.

More information

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating) .

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)



Get news and ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Comment